Can I Take Reishi Mushroom with Avodart (Dutasteride)?

What Is Dutasteride and Why Do People Combine It with Reishi?

Dutasteride 0.5 mg daily is FDA-approved for symptomatic benign prostatic hyperplasia (BPH) and is widely prescribed off-label for male pattern hair loss. It blocks both type 1 and type 2 isoforms of 5-alpha reductase, reducing serum dihydrotestosterone (DHT) by approximately 90% within two weeks of starting therapy, compared with finasteride's roughly 70% reduction of type 2 alone. [1]

Reishi mushroom is among the most commonly purchased botanical supplements in the United States. The 2022 Council for Responsible Nutrition Consumer Survey found that 21% of supplement users reported taking an adaptogen or functional mushroom product. Men with BPH or androgenetic alopecia often reach for reishi because preclinical data suggests it inhibits 5-alpha reductase activity through its triterpene constituents, making the rationale feel intuitive when they are already on dutasteride. [2]

Why the Combination Feels Logical but Warrants Scrutiny

A 2005 study published in the Journal of Ethnopharmacology tested Ganoderma lucidum oily fraction in testosterone-treated rats and found statistically significant reductions in prostate weight and 5-alpha reductase activity (P<0.05). [2] That preclinical signal draws men toward stacking reishi with dutasteride for an additive anti-DHT effect.

The problem is that reishi is not a single compound. Commercial extracts vary between polysaccharide-dominant (beta-glucan) and triterpene-dominant preparations, and the bioactive responsible for 5-alpha reductase inhibition in rats is not the same fraction responsible for platelet effects in humans.

FDA Status and Regulatory Context

Dutasteride carries FDA approval under NDA 021319. [3] Reishi is sold as a dietary supplement under DSHEA 1994 and is not FDA-approved for any clinical indication. No head-to-head clinical trial has evaluated the combination of Ganoderma lucidum extract with dutasteride in human subjects as of the date of this article.

The Pharmacokinetic Picture: Does Reishi Change How Dutasteride Is Absorbed or Cleared?

Dutasteride is metabolized primarily by hepatic CYP3A4, with a secondary pathway through CYP2D6. Its half-life is approximately five weeks at steady state. [1] Any supplement that modulates CYP3A4 could theoretically alter dutasteride plasma levels, raising or lowering DHT suppression and side-effect exposure.

CYP3A4 Inhibition by Reishi: What the Data Actually Show

A 2012 in-vitro study by Liu et al., published in Phytomedicine, screened Ganoderma lucidum polysaccharide fractions for CYP inhibitory activity. The triterpenoid ganoderic acid A showed weak inhibition of CYP3A4 activity at concentrations of 100 micromol/L. [4] Clinically meaningful CYP3A4 inhibition typically requires IC50 values well below 1 micromol/L in human liver microsomes. The concentrations needed to produce a pharmacokinetic interaction likely exceed what standard oral reishi doses deliver.

A standard commercial reishi capsule supplies 500 to 1,000 mg of extract, yielding triterpenoid fractions in the low-microgram systemic range after first-pass metabolism. Based on current in-vitro data, a clinically significant CYP3A4-mediated rise in dutasteride exposure is unlikely but cannot be fully excluded in people who consume very high-dose concentrated reishi extracts.

What This Means Practically

For the majority of men taking dutasteride 0.5 mg daily with a standard 1,000 mg reishi supplement, pharmacokinetic interference is not the primary concern. The pharmacodynamic effects described in the next section deserve more clinical attention.

Pharmacodynamic Interactions: Platelet Inhibition and Bleeding Risk

This is where the evidence becomes more clinically relevant. Reishi's beta-glucans and triterpenes both affect platelet function through separate mechanisms.

Platelet Aggregation Inhibition

A randomized crossover study by Yuen and Gohel, published in the American Journal of Chinese Medicine (2008, N=14), showed that Ganoderma lucidum extract at 1.44 g daily for four weeks significantly inhibited ADP-induced and collagen-induced platelet aggregation compared with placebo (P<0.05). [5] A second human study by Kimura et al. Confirmed reishi-derived adenosine as a direct inhibitor of platelet aggregation through cAMP elevation. [6]

Dutasteride itself does not directly affect coagulation or platelet function. However, men on dutasteride for BPH are typically 50 to 70 years old and often carry concurrent cardiovascular risk. That age group has the highest co-prescription rate for aspirin, clopidogrel, or direct oral anticoagulants (DOACs). Adding reishi on top of those agents stacks platelet-inhibitory pharmacodynamics.

The Surgical Timing Problem

The American Society of Anesthesiologists recommends disclosing all supplement use at least two weeks before elective procedures because of the antiplatelet activity documented for garlic, ginkgo, fish oil, and similar agents. [7] Reishi has not been explicitly named in every guideline, but the Yuen and Gohel platelet data place it in the same functional category. Men scheduled for transurethral resection of the prostate (TURP) or hair transplant surgery should stop reishi at least two weeks prior, regardless of dutasteride status.

Liver Enzyme Considerations

Dutasteride is a hepatically cleared drug, and postmarketing surveillance data include rare reports of elevated liver enzymes. [3] Reishi has its own hepatotoxicity signal. A 2010 case series in the International Journal of Molecular Medicine documented three patients with liver injury after consuming powdered whole reishi mushroom, distinct from standardized extracts. [8] The FDA MedWatch database includes additional hepatotoxicity reports for reishi-containing products. Combining two agents with hepatic liability is not cause for panic, but it argues for periodic liver function testing, especially in the first three to six months of concurrent use.

Does Reishi Actually Help BPH or Hair Loss on Top of Dutasteride?

This is worth addressing because men often add reishi for additive DHT suppression.

BPH Evidence for Reishi

A 2012 double-blind RCT by Noguchi et al. (N=88) tested a standardized Ganoderma lucidum extract at 6 mg daily for 12 weeks in men with lower urinary tract symptoms. The active group showed a statistically significant improvement in International Prostate Symptom Score (IPSS) compared with placebo (P<0.05). [9] No trial has compared reishi to dutasteride head-to-head, and no trial has tested the combination.

Hair Loss Evidence for Reishi

No peer-reviewed randomized controlled trial has established Ganoderma lucidum as an effective treatment for androgenetic alopecia in humans. The preclinical 5-alpha reductase inhibition data from 2005 remain the most cited basis for this use. [2] Men hoping to reduce dutasteride dose by adding reishi lack clinical trial support for that strategy.

The Additive Suppression Question

Dutasteride already suppresses circulating DHT by roughly 90% at 0.5 mg daily. [1] Even if reishi provided additional 5-alpha reductase inhibition, the incremental DHT reduction at that baseline is mathematically small. The risk-benefit calculation shifts against adding reishi purely for DHT suppression when dutasteride is already maximizing that pathway.

Immune Modulation: A Separate Layer of Concern

Reishi polysaccharides are classified as biological response modifiers. They up-regulate natural killer cell activity, macrophage activation, and interleukin-2 production. [10] Dutasteride has no direct immunologic mechanism, so this is not a pharmacodynamic interaction between the two agents. The concern is indirect.

When Immune Modulation Matters

Men with autoimmune conditions, organ transplants, or active malignancy who take dutasteride should discuss reishi use with their specialist before starting, because immune-stimulating botanicals can alter the activity of immunosuppressive medications or the disease course itself. The combination of reishi plus dutasteride is not the trigger here. The immune modulation from reishi alone is the issue that requires specialist input in those subgroups.

Men on Prostate Cancer Protocols

Dutasteride has been studied for prostate cancer chemoprevention. The REDUCE trial (N=8,231) evaluated dutasteride 0.5 mg over four years and found a 22.8% relative risk reduction in biopsy-detected prostate cancer in the dutasteride group versus placebo. [11] Men who are on dutasteride as part of an oncology-adjacent monitoring protocol should have their oncologist review any supplement additions, including reishi, because reishi has its own body of prostate cancer research that could interact with monitoring endpoints.

Practical Guidance: Monitoring and What to Do If You Are Already Taking Both

Most men who are taking dutasteride 0.5 mg daily alongside a standard reishi supplement (500 to 1,000 mg daily) and who have no bleeding risk, no anticoagulant co-prescription, and normal liver function at baseline face a low probability of a serious adverse event from this combination. Low probability is not zero probability.

Steps Before Starting the Combination

1. Tell your prescriber you are taking or plan to take reishi. This conversation takes under two minutes and removes most of the risk.
2. Review your full medication list for aspirin, NSAIDs, clopidogrel, warfarin, rivaroxaban, apixaban, or other anticoagulants. If any are present, do not add reishi without explicit prescriber approval.
3. Obtain a baseline liver function panel (ALT, AST, total bilirubin) if you have not had one in the past 12 months.
4. Note any upcoming surgical procedures. Stop reishi at least 14 days before surgery.

Monitoring During Concurrent Use

Repeat liver function testing at three months after starting the combination. Report any unusual bruising, prolonged bleeding from minor cuts, or changes in urinary symptoms to your prescriber. The FDA MedWatch portal accepts consumer reports for supplement-related adverse events, and filing a report contributes to the post-market safety database for products like reishi. [12]

Dosing Considerations

No formal dose-separation window is required for reishi and dutasteride because their interaction is pharmacodynamic rather than pharmacokinetic. Taking them at different times of day does not meaningfully reduce platelet-related risk. Dose reduction of reishi, rather than timing separation, is the relevant variable if bleeding risk is elevated.

What the Guidelines Say About Supplement Use with 5-Alpha Reductase Inhibitors

The American Urological Association 2021 guideline on BPH management (updated 2023) recommends clinicians ask patients about dietary supplement use at every visit, given the high prevalence of supplement co-administration in the BPH population. [13] The guideline does not name reishi specifically, but the general principle of disclosure applies directly.

The American Hair Loss Association and the International Society of Hair Restoration Surgery do not list reishi as a recommended adjunct to dutasteride in their current clinical statements. Saw palmetto, another 5-alpha reductase modulator, is the botanical most discussed in that literature, with some evidence of modest effect. Reishi occupies a different mechanistic profile and should not be assumed to carry the same risk-benefit data.

The Natural Medicines database (Therapeutic Research Center) rates the evidence for reishi-drug interactions as "insufficient" for most specific drug pairs, including dutasteride, while flagging theoretical concerns for anticoagulants, immunosuppressants, and antihypertensives. [14]

Direct Guidance from Clinical Literature

A 2019 review by Wachtel-Galor et al. In Herbal Medicine: Biomolecular and Clinical Aspects stated: "Ganoderma lucidum may potentiate the effects of antithrombotic drugs and should be used with caution in patients taking anticoagulant or antiplatelet therapies." [15] That caution is the most directly applicable published clinical guidance to the reishi-plus-dutasteride population.

Special Populations and Edge Cases

Men with Elevated PSA

Dutasteride suppresses prostate-specific antigen (PSA) by approximately 50% after six months of use. [1] Clinicians double the measured PSA to estimate the true value during dutasteride therapy. Reishi supplementation does not appear to alter PSA independently in current data, but any botanical with prostate-active mechanisms deserves documentation in the chart to avoid confounding PSA interpretation.

Older Adults (Age 65 and Above)

Hepatic CYP3A4 activity declines with age, which already slows dutasteride clearance. If reishi contributes even marginal additional CYP3A4 inhibition, the effect is more pronounced in older men with reduced baseline enzyme capacity. The clinical consequence is likely small, but starting reishi at the lowest effective dose (500 mg versus 1,000 mg daily) is a reasonable precaution in men over 65 taking dutasteride.

Men Considering Prostate Biopsy

Because both reishi and dutasteride affect prostate tissue markers in different ways, inform your urologist of both before any biopsy procedure. Reishi's platelet-inhibitory effect is relevant to post-biopsy bleeding risk. Dutasteride's PSA suppression is relevant to biopsy indication thresholds.